Given its role in DNA repair, RAD50 presents an attractive target for cancer therapy. Inhibitors targeting the MRN complex, or RAD50 specifically, could potentially sensitize cancer cells to DNA-damaging treatments. However, the challenge lies in selectively targeting cancer cells without harming normal cells that also rely on RAD50 for DNA repair. Ongoing research aims to develop therapies that can exploit the unique vulnerabilities of RAD50-deficient tumors.
